Imaging of cell-based therapy using89 zr-oxine ex vivo cell labeling for positron emission tomography

Yutaka Kurebayashi, Peter L. Choyke, Noriko Sato

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


With the rapid development of anti-cancer cell-based therapies, such as adoptive T cell therapies using tumor-infiltrating T cells, T cell receptor transduced T cells, and chimeric antigen receptor T cells, there has been a growing interest in imaging technologies to non-invasively track transferred cells in vivo. Cell tracking using ex vivo cell labeling with positron emitting radioisotopes for positron emission tomography (PET) imaging has potential advantages over single-photon emitting radioisotopes. These advantages include intrinsically higher resolution, higher sensitivity, and higher signal-to-background ratios. Here, we review the current status of recently developed Zirconium-89 (89Zr)-oxine ex vivo cell labeling with PET imaging focusing on its applications and future perspectives. Labeling of cells with89Zr-oxine is completed in a series of relatively simple steps, and its low radioactivity doses required for imaging does not interfere with the proliferation or function of the labeled immune cells. Preclinical studies have revealed that 89Zr-oxine PET allows high-resolution in vivo tracking of labeled cells for 1-2 weeks after cell transfer both in mice and non-human primates. These results provide a strong rationale for the clinical translation of 89Zr-oxine PET-based imaging of cell-based therapy.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
Issue number1
Publication statusPublished - 2021
Externally publishedYes


  • Cell tracking
  • Cell-based therapy
  • Positron emission tomography
  • Zirconium-89
  • Zirconium-89 oxine

ASJC Scopus subject areas

  • Biotechnology
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)


Dive into the research topics of 'Imaging of cell-based therapy using89 zr-oxine ex vivo cell labeling for positron emission tomography'. Together they form a unique fingerprint.

Cite this